ValuEngine upgraded shares of Precipio (NASDAQ:PRPO) from a strong sell rating to a sell rating in a report released on Friday.
Shares of Precipio (PRPO) traded down $0.04 during trading on Friday, reaching $1.07. The company had a trading volume of 30,721 shares, compared to its average volume of 43,021. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.07 and a current ratio of 0.08. The company has a market capitalization of $10.34 and a price-to-earnings ratio of -0.05. Precipio has a 1 year low of $0.99 and a 1 year high of $28.16.
Precipio (NASDAQ:PRPO) last announced its quarterly earnings data on Monday, November 20th. The biotechnology company reported ($1.22) earnings per share for the quarter. Precipio had a negative net margin of 1,113.78% and a negative return on equity of 50,943.55%.
ILLEGAL ACTIVITY NOTICE: “Precipio (PRPO) Upgraded by ValuEngine to Sell” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/03/precipio-prpo-upgraded-by-valuengine-to-sell.html.
Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.